Please provide your email address to receive an email when new articles are posted on . Moderate exacerbations shared similar characteristics with severe exacerbations. Lung function, limitations and ...

Candidate has potential to be a first-in-class treatment offering biologic-like disease control from an oral small moleculeRegulatory submission ...

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers. Two posters presented at ...

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history. Dupilumab was shown to consistently ...

Pediatrics patients with asthma who have to undergo surgery are at risk for complications. A real-world study assessed how pediatric patients with moderate to severe asthma responded to the use ...

Please provide your email address to receive an email when new articles are posted on . 42.6% of patients filled a SABA prescription 30 days before an exacerbation, and 61.4% did so within 30 days ...

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of ...

A meta‑analysis of 15 trials found that among the biologics evaluated, tezepelumab yielded the greatest reduction in exacerbations compared with placebo (mean difference [MD], -0.81; 95% CI, -1.09 to ...

WILMINGTON, Del.--(BUSINESS WIRE)--AIRSUPRA™ (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce ...

Primary Author: Manan Shah and Co-Author: Shyam Saravanan, both Drexel University College of Medicine. Credit: J. Kang. The findings challenge previous beliefs that ICIs may exacerbate inflammatory ...

Continuous exposure to dogs in children with asthma is associated with a risk for asthma exacerbations but does not increase the risk for moderate-to-severe asthma.

Credit: Thinkstock. Investigators assessed a real-world pediatric patients with asthma who used biologic therapy to identify their response to prescribed biologics and reasons for discontinuation of ...